Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

NATUREX announces the temporary unavailibility of Jacques DIKANSKY, President and CEO



Avignon, 13thApril 2012 - NATUREX, world leader in specialty plant-based natural ingredients, informs its shareholders of the temporary unavailability for health reasons of Jacques DIKANSKY, President and CEO of the Company.


The Board of Directors of NATUREX S.A. acknowledged this situation during its meeting on 13th April 2012.


In accordance with the Company's method of governance set out in the articles of association, Thierry LAMBERT, in his capacity as director and Vice-President, will chair the meetings of the Board of Directors during this period and will ensure the proper execution of the Board's work in close collaboration with its members, including Stéphane DUCROUX, Vice-President of NATUREX Inc. and Paul LIPPENS, independent director and Chairman of FINASUCRE.


From an operational standpoint, the NATUREX group's centralised organisation and the integrated management of the various subsidiaries will make it possible to continue with the action plans that were set up for 2012, despite the temporary absence of Jacques DIKANSKY, without any consequences on the Groups' business operations.


The management team, comprised for many years now of highly experienced executives, will provide, along with Thierry LAMBERT, the smooth running of the group’s business in coordination with the different subsidiaries, and in particular will continue with the integration process of the acquired companies (BURGUNDY in France and in Spain, PEKTOWIN in Poland and VALENTINE in India).




  • Financial agenda




    • 1st quarter sales 2012 : 26th April 2012




    • 1st quarter results 2012 : 29th May 2012




    • Shareholders meeting : 8th June 2012 in Paris




If you would lik e to receive financial information about Naturex by e-mail, go to: www.naturex.com




Naturex has been listed since October 1996 on NYSE Euronext Paris, Compartment B (MidCaps)


Number of shares comprising the capital: 7,711,076




  • 6,953,768 ordinary shares (ISIN FR0000054694)




  • 757,308 preferred shares (ISIN FR0010833251)



Naturex is a component of the CAC Small and Gaïa indexes.


Naturex is eligible for "long only" Deferred Settlement Service (SRD).


Naturex has implemented a Sponsored Level I American Depositary Receipt (ADR) program,

which trades on over-the-counter market in the United States under symbol NTUXY.


TICKER: NRX - Reuters : NATU.PA - Bloomberg : NRX:FP - DR Symbol: NTUXY




About Naturex


NATUREX is a global leader in specialty plant-based natural ingredients.


The Group is organised around three strategic markets (food & beverage, nutrition & health and personal care) and produces and markets specialty plant-based ingredients for the food, nutraceutical, pharmaceutical and cosmetic industries.


NATUREX’s head office is based in Avignon, France. The company employs more than 1,000 people with high-performance manufacturing operations across 15 sites in Europe (France, Italy, Spain, the United Kingdom, Switzerland, Poland), as well as in Morocco, the United States, Brazil, Australia and India. It also has a global presence through a dedicated network of sales offices in 21 countries (France, Italy, Spain, Morocco, the United Kingdom, Belgium, Germany, Poland, Russia, U.A.E., Thailand, Singapore, Japan, China, Korea, Australia, the United States, Canada, Brazil, Mexico and India).


NATUREX's development is supported by positive underlying trends linked to a fast-growing demand for natural products and its capacity to provide manufacturers customised solutions to meet the requirements of their end consumers. The Group's strength lies in its positioning with specific products which constitute niche markets, supported by strong sourcing capacity and sustained research & development.


















  • Contacts
 
Jacques Dikansky

President and Chief Executive Officer

Tel.: +33 (0)4 90 23 96 89

[email protected]
 

Thierry Lambert

Vice-President and Chief Financial Officer

Tel.: +33 (0)4 90 23 96 89

[email protected]
Carole Alexandre

Investor Relations

Tel.: +33 (0)4 90 23 78 28

[email protected]
Anne Catherine Bonjour

Actus Finance Press Relations

Tel.: +33 (0)1 53 67 36 93

[email protected]

Information réglementée
Communiqués au titre de l'obligation d'information permanente :

- Autres communiqués

Communiqué intégral et original au format PDF :


http://www.actusnews.com/documents_communiques/ACTUS-0-27362-2012.04.13-temporary-unavailibility-of-mr-dikansky.pdf

<!-- 90 -->

© Copyright Actusnews Wire

Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com

Receive by email the next press releases of the company by registering on www.actusnews.com, it's free


<br/><p>Quelle: <a href="http://www.actusnews.com/" target="_blank" rel="nofollow">Actusnews</a></p>
Like: 0
Teilen

Kommentare